Impact of Shipment Delays at the Aitaka Plant on Cardiovascular Products
First written in FY2019-Q1. 2 of 4 entries say "Mitigated", first in FY2019-Q3. Latest entry: FY2019.
0 other companies' latest entry also says "Mitigated".
- FY2019MitigatedAnnual report
「In Japan, the Hospital Company's surgical business and alliance business involving partnerships with pharmaceutical companies performed well. However, revenue declined at the Cardiovascular Company because, although shipment delays at the Ashitaka Plant that arose during the first half had normalized in the second half, the company was affected by those delays and official price revisions. 」
The company stated that shipment delays at the Ashitaka Plant had normalized in the second half and that the impact had eased, but Japan revenue declined for the full year due to the effects of the delays and official price revisions. - FY2019-Q3MitigatedAnnual report
「In addition, some products experienced shipment delays from the Ashitaka Plant from May 2018 onward, but shipments stabilized from October onward and sales also showed signs of recovery.」
The company stated that shipments from the Ashitaka Plant had stabilized and sales were recovering from October onward, indicating that the impact had eased. - FY2019-Q2WorsenedAnnual report
「In Japan, the Hospital Company's surgical business and alliance business involving partnerships with pharmaceutical companies performed well. However, revenue declined company-wide because, in addition to the impact of official price revisions, some products at the Cardiovascular Company were delayed in shipment from the Ashitaka Plant. Overseas revenue increased despite the impact of shipment delays at the Ashitaka Plant, driven by strong performance in the Cardiovascular Company's neurovascular business and the Hospital Company's alliance business, as well as products for blood centers from the Blood Management Company.」
The company stated that shipment delays at the Ashitaka Plant affected not only the domestic Cardiovascular Company but also overseas revenue, explicitly broadening the scope of the impact. - FY2019-Q1First statedAnnual report
「In Japan, the Hospital Company's pain management business and alliance business involving partnerships with pharmaceutical companies performed well. However, revenue declined company-wide because, in addition to the impact of official price revisions, some products at the Cardiovascular Company were delayed in shipment from the Ashitaka Plant.」
Shipment delays for some products from the Ashitaka Plant were cited, together with official price revisions, as factors behind the decline in Japan revenue at the Cardiovascular Company.